News Release - Siegfried
News Release - Siegfried
News Release - Siegfried
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>News</strong> <strong>Release</strong><br />
The <strong>Siegfried</strong> Group sells Biologics Division<br />
As already announced, the <strong>Siegfried</strong> Group in Zofingen (SWX: SFZN) sells its Business Unit<br />
Biotechnology. The buyer is an Indian company, Avesta Biotherapeutics and Research Pvt. Ltd.<br />
(ABRPL). The acquisition is retroactively valid by October, 1st 2007. The approx. 50 employees<br />
in Berlin-Kleinmachnow will be taken over. The purchase price was not disclosed. <strong>Siegfried</strong>-<br />
CEO Douglas C. Günthardt: “the sale of our Biotechnology Division is a further step in the concentration<br />
process of the <strong>Siegfried</strong> Group. We will focus on two core areas, namely the manufacture<br />
of active pharmaceutical ingredients for the worldwide life science industry and the development<br />
and manufacture of complex generics. In the future, we will apply all our resources to<br />
these business areas.”<br />
Zofingen, October, 5th 2007<br />
For further information:<br />
Dr. Richard Schindler, Chief Financial Officer of the <strong>Siegfried</strong> Group<br />
Tel. +41 (0)62 746 11 35, Fax +41 (0)62 746 11 03<br />
<strong>Siegfried</strong> Holding AG<br />
Untere Brühlstrasse 4<br />
CH - 4800 Zofingen<br />
Phone + 41 62 746 11 11<br />
Fax + 41 62 746 11 04<br />
www.siegfried-holding.com<br />
About <strong>Siegfried</strong><br />
Active in Life Science markets, the <strong>Siegfried</strong> Group is a global manufacturer and pharmaceutical<br />
products. With production facilities located in Switzerland, Germany, Malta and the USA, <strong>Siegfried</strong><br />
currently has approximately 950 employees and achieved annual sales of approx. CHF<br />
320 million in 2006. The <strong>Siegfried</strong> Holding AG is listed on the Swiss Exchange in Zürich (SWX:<br />
SFZN).<br />
<strong>Siegfried</strong> integrates two pharmaceutical business units. <strong>Siegfried</strong> Actives develops and produces<br />
both exclusive active pharmaceutical ingredients for the pharma industry and standard<br />
APIs. <strong>Siegfried</strong> Generics produces complex generic products.<br />
1
Seite 2<br />
About Avesta Biotherapeutics and Research Pvt. Ltd. (ABRPL)<br />
Avesta Biotherapeutics and Research Pvt. Ltd. (ABRPL) is a joint venture (JV) between<br />
Avestha Gengraine Technologies Pvt Ltd. (Avesthagen) and Meditab Specialities Ltd.<br />
(of CIPLA group). The JV, ABRPL, based in Bangalore, will manufacture a series of<br />
biopharmaceuticals primarily for the Indian market. In addition, the venture will exploit<br />
opportunities in biological Contract Manufacturing worldwide.“
Change language